γ2 GABA<sub>A</sub>R Trafficking and the Consequences of Human Genetic Variation

Joshua M. Lorenz-Guertin, Matthew J. Bambino and Tija C. Jacob*

Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States

GABA type A receptors (GABA<sub>A</sub>Rs) mediate the majority of fast inhibitory neurotransmission in the central nervous system (CNS). Most prevalent as heteropentamers composed of two α, two β, and a γ2 subunit, these ligand–gated ionotropic chloride channels are capable of extensive genetic diversity (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3). Part of this selective GABA<sub>A</sub>R assembly arises from the critical role for γ2 in maintaining synaptic receptor localization and function. Accordingly, mutations in this subunit account for over half of the known epilepsy-associated genetic anomalies identified in GABA<sub>A</sub>Rs. Fundamental structure–function studies and cellular pathology investigations have revealed dynamic GABA<sub>A</sub>R trafficking and synaptic scaffolding as critical regulators of GABAergic inhibition. Here, we introduce in vitro and in vivo findings regarding the specific role of the γ2 subunit in receptor trafficking. We then examine γ2 subunit human genetic variation and assess disease related phenotypes and the potential role of altered GABA<sub>A</sub>R trafficking. Finally, we discuss new-age imaging techniques and their potential to provide novel insight into critical regulatory mechanisms of GABA<sub>A</sub>R function.

Keywords: GABA<sub>A</sub> receptor, trafficking, genetic variation, human, epilepsy, imaging

INTRODUCTION

The adult central nervous system (CNS) is critically dependent on fast inhibitory neurotransmission evoked by GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs). GABA<sub>A</sub>Rs are ligand-gated ionotropic chloride (Cl<sup>−</sup>) channels ubiquitously expressed throughout the CNS that play a fundamental role in restraining and sculpting neuronal activity. Disruptions in GABA<sub>A</sub> dependent neurotransmission leads to insufficient inhibitory effects throughout the brain, contributing to the pathogenesis of epilepsy, neurodevelopmental disorders, depression, schizophrenia and stroke (Hines et al., 2012). Activation of GABA<sub>A</sub>Rs by the neurotransmitter GABA induces ion channel opening, Cl<sup>−</sup> influx, and subsequent membrane hyperpolarization. These heteropentameric structures are predominantly composed of two α (α1-6), two β (β1-3), and either a γ (γ1-3) or a δ subunit (Olsen and Sieghart, 2009) (Figures 1A,B). GABA<sub>A</sub>Rs belong to the Cys-loop superfamily of pentameric ligand-gated ion channels (pLGICs) including strychnine-sensitive glycine receptors, nicotinic acetylcholine (nACh) receptors, and 5-hydroxytryptamine type-3 (5-HT3) receptors. Individual subunits have a common structure consisting of a large N-terminus extracellular domain (ECD) that participates in endogenous ligand binding, a transmembrane domain (TM) comprised of four α-helical regions (M1–4) and a
barely extruding extracellular C-terminus. The M2 region of the subunits forms the ion channel pore. The hydrophobic M regions are connected by a small intracellular loop between M1-M2 and a much larger intracellular domain (ICD; previously termed intracellular loop) between M3 and M4 (Sigel and Steinmann, 2012) that mediates interactions with intracellular proteins critical for receptor trafficking and synaptic clustering (Figure 1C). Recently, GABA<sub>A</sub>R structures for the human β3 homopentamer bound to benzamidine (Miller and Aricescu, 2014), chimeric α5TM/β3ECD bound to the neurosteroid allopregnanolone (Miller et al., 2017), and human α1β2γ2 heteropentamer bound to GABA and the benzodiazepine site antagonist Flumazenil (Zhu et al., 2018) were resolved, advancing our growing understanding of GABA<sub>A</sub>R molecular architecture. Importantly, nearly all pLGIC family structural data lacks the large ICD (Nemecz et al., 2016) (exception 5-HT<sub>3</sub> receptor; Hassaine et al., 2014), leaving functionally relevant information about this region left undiscovered.

Presynaptic terminal release of GABA onto postsynaptically clustered GABA<sub>A</sub>Rs initiates fast, transient receptor activation. In contrast, activation of extrasynaptic GABA<sub>A</sub>Rs by ambient "spill over" GABA generates a persistent tonic current (Figure 1D). Most GABA<sub>A</sub>Rs evoking fast synaptic inhibition in the mature cortex contain α1β2γ2 subunits, although α/β content can vary widely (Olsen and Sieghart, 2009), prompting a unifying role of γ2 in synaptic function. Importantly, the benzodiazepine drug class selectively binds between the interface of a γ2 subunit and either an α1/2/3/5 subunit to potentiate GABA<sub>A</sub>R function and elicit behavioral effects including sedative/hypnotic, anti-convulsant, myorelaxant, and/or anti-anxiety effects (Vinkers and Olivier, 2012) (Figures 1A,B). Here we summarize (1) known molecular interactors and mechanisms regulating γ2 trafficking (2) the importance of this subunit physiologically and human γ2 genetic variants compromising structure and function in vitro and in vivo and (3) application of modern imaging techniques to discover novel insight into synaptic GABA<sub>A</sub>R modulation.

### γ2 SUBUNIT TRAFFICKING AND INTERACTORS

#### Biosynthetic Trafficking and Insertion

During biosynthesis, GABA<sub>A</sub>R subunits are first assembled in the endoplasmic reticulum (ER) and then transported to the Golgi apparatus (Golgii) for further maturation (Figure 2). Forward trafficking of γ2-GABA<sub>A</sub>Rs from the ER is negatively regulated by Cleft lip and palate transmembrane protein (CLPTM1) in vitro and in vivo (Figure 2) (Ge et al., 2018). Overexpressing CLPTM1 reduces surface and synaptic levels of γ2, resulting in reduced amplitude and frequency of inhibitory postsynaptic current (IPSC), where the opposite effect is seen by CLPTM1 knockdown (KD). Importantly, CLPTM1 also regulates tonic inhibition and interacts with the extrasynaptic subunits α4 and δ, suggesting this protein non-selectively binds many GABA<sub>A</sub>R subtypes. Upon entry into the Golgi, the γ2 subunit undergoes palmitoylation via the Golgi-specific DHHC zinc finger enzyme (GODZ; also known as ZDHHC3) (Keller et al., 2004; Fang et al., 2006). This process is key for receptor clustering, innervation, and inhibitory strength in vitro and in vivo (Keller et al., 2004; Fang et al., 2006; Kilpatrick et al., 2016). GABA<sub>A</sub>R forward trafficking to the cell surface depends on the microtubule-dependent molecular motor kinesins (KIFs) (Figure 2). The KIF21B protein co-precipitates with the GABA<sub>A</sub>R γ2 subunit (Labonte et al., 2014). RNA KD of KIF21B reduces receptor surface levels and the intensity of extrasynaptic γ2 clusters, but does not affect synaptic GABA<sub>A</sub>Rs levels. Additionally, the KIF5 family plays a critical role in trans-Golgii to surface GABA<sub>A</sub>R trafficking (Twelvetrees et al., 2010). Conditional knockout (KO) of KIF5A in mice results in deficits of GABA<sub>A</sub>R plasma membrane levels, epilepsy phenotypes, and high lethality rate within 21 days postnatal (Nakajima et al., 2012).

Notably, KIF5A (not KIF5B, KIF5C) selectively interacts with the GABA<sub>A</sub>R-associated protein (GABARAP) in vivo (Nakajima et al., 2012). The well-characterized GABARAP (Figure 2) is part of the ubiquitin-like protein (UBL) family implicated in numerous cellular processes (van der Veen and Ploegh, 2012). GABARAP interacts with GABA<sub>A</sub>R γ subunits and microtubules, is heavily localized at the Golgi apparatus and cell surface (Wang et al., 1999), and overexpression augments GABA<sub>A</sub>R plasma membrane levels (Leil et al., 2004). However, GABARAP KO mice have unhindered distribution of γ2-GABA<sub>A</sub>Rs and gephyrin, suggesting functional redundancy with other trafficking proteins (O’Sullivan et al., 2005). Some evidence suggests GABARAP preferentially associates with serine phosphorylated γ2-GABA<sub>A</sub>Rs, while dephosphorylation by protein phosphatase 1 (PP1) decreases this interaction (Qian et al., 2011).

A number of GABARAP interacting proteins mediate GABA<sub>A</sub>R trafficking or localization (Figure 2). For instance, increased association with the PDZ domain-containing protein GRIP is seemingly involved in NMDA receptor-dependent GABA<sub>A</sub>R synaptic plasticity (Marsden et al., 2007). The phospholipase C-related catalytically inactive proteins 1 and 2 (PRIP1/2) and the N-ethylmaleimide-sensitive factor ATPase (NSF) interact with GABA<sub>A</sub>Rs both indirectly via GABARAP and directly with β subunits (Figure 2) (Kenematsu et al., 2002; Terunuma et al., 2004; Goto et al., 2005; Mizokami et al., 2007). NSF is a key component of SNARE-mediated fusion and is involved in receptor cell surface transit (Chou et al., 2010). Notably, the γ2 subunit and PRIP share an overlapping binding site on GABARAP (Kenematsu et al., 2002). PRIP1/2 KO mice demonstrate diminished benzodiazepine sensitivity and Zn<sup>2+</sup> modulation concurrent with lower plasma membrane GABA<sub>A</sub>R expression, consistent with impaired γ2 subunit trafficking. KO of PRIP-1, the primary brain subtype, leads to mice displaying an epileptic phenotype that can be successfully suppressed by diazepam (DZP), but interictal discharges persist (Zhu et al., 2012). Interestingly, DZP potentiation of miniature inhibitory postsynaptic currents (mIPSC) remains unchanged, but baseline and DZP potentiated tonic GABA current amplitude in PRIP-1 KO neurons was reduced. PRIP-1...
KO and PRIP1/2 double KO mice show anxiety-related behaviors and abnormal locomotion related to GABA_{A}R dysfunction and reduced benzodiazepine sensitivity. Recently the Rho GTPase Activating Protein 32 (ARHGAP32) isoform 1 (PX-RICS) was shown to form an adaptor complex with GABARAP and the scaffold proteins 14-3-3/ζ to facilitate γ_{2}-GABA_{A}R_{S} forward trafficking via dynein/dynactin and promote surface expression (Nakamura T. et al., 2016). KO of PX-RICS in mice generates an Autism Spectrum Disorder (ASD) phenotype with increased susceptibility to kainate-induced epileptic seizures, decreased GABA_{A}R plasma membrane levels, and lowered mIPSC amplitude. Transgenic overexpression of 14-3-3ζ in mice protects against neuronal death caused by prolonged seizures (Brennan et al., 2013). In contrast, 14-3-3ζ mutations or deletions have been identified in patients with pathology associated with GABA_{A}R deficits including schizophrenia, autism and generalized epilepsy (Tenney et al., 2011; Fromer et al., 2014; Toma et al., 2014).

**Synaptic Accumulation and Functional Regulation**

Following insertion at the plasma membrane, γ_{2}-GABA_{A}Rs undergo Brownian diffusion until interaction with the inhibitory postsynaptic scaffolding protein gephyrin causes constraint and accumulation (Figures 1D, 2). Specifically, GABA_{A}R α1/2/3/5 and β2/3 subunits (at lower affinity) mediate gephyrin-receptor binding (Trettet et al., 2008, 2011; Mukherjee et al., 2011; Kowalczyk et al., 2013; Brady and Jacob, 2015). While no direct interaction between γ and gephyrin has been identified, the synaptic levels of these proteins are intimately tied, shown by KO studies of gephyrin (Kneussel et al., 1999) and γ_{2} (Schweizer et al., 2003). Interestingly, chimeric studies indicate...
FIGURE 2 | GABAR trafficking and key interacting proteins at GABAergic synapses. The process of GABAR synthesis, assembly and forward trafficking is highly regulated. Forward trafficking of γ2-GABARs from the ER is negatively regulated by CLPTM1. Subunits are assembled into pentameric receptors in the endoplasmic reticulum (ER) where proper folding allows receptors to avoid proteosomal degradation and exit to the Golgi. In the Golgi, palmitoylation of γ subunits by the palmitoyltransferase GODZ is a key step in promoting forward trafficking to the synapse. GABARAP interacts with γ subunits and microtubules and overexpression augments receptor plasma membrane levels. PX-RICS forms an adaptor complex with GABARAP to facilitate γ2-GABARs forward trafficking. PRIP1/2 and NSF interact with GABARs both indirectly via GABARAP and directly with β subunits. The kinesin KIF5 is the main microtubule (MT)-dependent motor transporting inhibitory synapse components although recent work shows KIF21 contributes to extrasynaptic receptor delivery. LH4 forms a complex between γ2 and NL2. NL2 is central in GABAR synapse development via its trans-synaptic association with axonal neurexins and also binds gephyrin. GABARs primarily undergo clathrin-dependent endocytosis via β and γ subunit interactions with the clathrin-adaptor protein 2 (AP2) complex. Phosphorylation of AP2-interaction motifs within receptor subunits increases cell-surface receptor levels and enhances GABAR neurotransmission by reducing AP2 binding to receptors. After internalization, clathrin-coated vesicles fuse with early endosomes, allowing for subsequent receptor recycling or targeting for degradation in lysosomes. CAML interaction with the γ2 subunit promotes forward trafficking and recycling. Ubiquitination of GABAR contributes to lysosomal targeting, with the ubiquitin E3 ligase RNF34 directly interacting with the γ2 subunit. Protein abbreviations: CAML (calcium-modulating cyclophilin ligand), CLPTM1 (Cleft lip and palate transmembrane protein), GABARAP (GABAAR - associated protein), GODZ (Golgi-specific DHHC zinc finger enzyme), KIF 5/21 (microtubule-dependent molecular motor kinesins), LH4 (lipoma HMGIC fusion partner-like protein 4), NL2 (neurexin 2), NSF (N-ethylmaleimide-sensitive factor ATPase), PRIP (phospholipase C-related catalytically inactive proteins), PX-RICS [Rho GTPase Activating Protein 32 (ARHGAP32) isoform 1], RNF34 (ring finger protein 34 E3 ligase).
the γ2 M4 is sufficient to cause GABAₐR accumulation opposite GABAergic terminals, while the large ICD of γ2 is necessary for gephyrin recruitment and rescue of synaptic function in γ2 KO cultured neurons (Allred et al., 2005). It is likely that an indirect interaction occurs between γ2 and gephyrin across a bridge of other key synaptic proteins. Recently, six unrelated patients were identified with microdeletions in the gephyrin gene resulting in a range of neurodevelopmental deficits including ASD, schizophrenia or epilepsy (Lionel et al., 2013). The recently discovered GABAₐR regulatory Lhfp1 (GARLH) family proteins lipoma HMGIC fusion partner-like 3 and 4 (LH3 and LH4) forms a native complex between (GARLH) family proteins lipoma HMGIC fusion partner-like 2 (GARLH2) and gephyrin (Yamasaki et al., 2017). NL2 is central in GABAₐR synapse development via its trans-synaptic association with axonal neurexins (Sudhof, 2008). Diminishing LH4 levels in culture and in vivo dramatically reduced γ2-GABAₐR and gephyrin synaptic clustering and inhibitory strength (Davenport et al., 2017; Yamasaki et al., 2017). Curiously, despite the dramatic reduction in synaptic inhibition, epilepsy susceptibility or overt behavioral phenotypes in these mice have yet to be reported in the constitutive LH4 KO mouse. Importantly, gephyrin is known to directly bind the intracellular domain of NL2 (Poulopoulos et al., 2009). Thus γ2 subunit-LH4-NL2-gephyrin interactions could provide a molecular framework to support γ2's role in GABAₐR synaptic recruitment and maintenance.

Synaptic plasticity, or the dynamic modulation of synaptic output, is heavily influenced by receptor phosphorylation via altering channel function or receptor trafficking. Phosphoregulation of γ2 S327 is an important mediator of GABAₐR retention at synapses. Detailed electrophysiology and in vivo studies have identified the PKCε isoform specifically phosphorylates the γ2 S327 residue (Figures 1C, 2), ultimately fine-tuning responsiveness to ethanol and benzodiazepines (Qi et al., 2007). Additionally, protocols that induce calcium-entry via glutamate application, strong NMDA receptor activation, or robust neuronal activity enhance receptor lateral mobility, decrease synaptic cluster size, and reduce mIPSC amplitude via the phosphatase calcineurin (CaN) (Bannai et al., 2009) and dephosphorylation of the γ2 subunit S327 residue (Figures 1C, 2) (Muir et al., 2010). More broadly, activation of all PKC isoforms by 1 h PMA (PKC activator; 30 nM) treatment decreases surface γ2-GABAₐR levels that can be reversed by specific inhibition of PKCε catalytic activity in HEK cells and PKCε specific activation reduces GABAₐR current amplitude (Chou et al., 2010). This effect was in part attributed to changes in GABAₐR trafficking occurring though PKCε association and phosphorylation of NSF. The scaffolding protein 14-3-3-0 acts as a bridge for the PKCγ isoform to interact with γ2 in cerebellar Purkinje neurons and N2a cells (Qian et al., 2012). 14-3-3-0 KD in mice by siRNA microinjection reduces γ2-GABAₐR overall serine phosphorylation, while KD of 14-3-3-0 or PKCγ reverses the PMA (200 nM, 30 min) induced upregulation of C cell surface expression in N2a cells. These apparently conflicting reports on PKC kinase family modulation highlights the complexity of this signaling pathway in γ2-GABAₐR regulation, with varied effects dependent on the pharmacological agents used, treatment times, model, and PKC isoforms.

An important consideration for γ2 subunit regulation is its presence in a short (γ2S) or long (γ2L) isoform; the γ2L isoform has 8 additional amino acids (LLRMFSFK) in the large ICD with the serine site (S343) capable of being phosphorylated by Protein kinase C (PKC) and Calcium/calmodulin-dependent protein kinase type II (CaMKII) (Figure 1C) (Whiting et al., 1990; Moss et al., 1992; McDonald and Moss, 1994). Expression levels of γ2S remain constant throughout development, while γ2L levels increase during neuronal maturation (Wang and Burt, 1991). Early in vitro expression studies found that the additional amino acids in the γ2L subunit may play a role in the response to diazepam and be critical for ethanol enhancement of GABA current (Wafford et al., 1991). Both mutation of S343 to a phosphomimetic aspartate or to non-phosphorylatable valine resulted in cell surface trafficking of γ2L when expressed alone, similar to γ2S (Boileau et al., 2010). This work also proposed an accessory protein role for γ2S as an external modulator of GABAₐR function to confer zinc blockade protection for receptors. When comparing synaptic clustering of γ2L vs. γ2S subunit large ICD (partial subunit chimeras) in spinal cord neurons, postsynaptic γ2L ICD chimera accumulation is higher, and can be enhanced by PKC activation by phorbol ester phorbol-12,13-dibutyrate (PDBu) and reversed by mutating the S343 residue of γ2L (Meier and Grantyn, 2004). The physiological role of CaMKII direct phosphorylation on γ2 has not yet been described, although CaMKII is required for a type of inhibitory long term potentiation (iLTP) in Purkinje neurons known as rebound potentiation (Kano et al., 1996) and increased association between the γ2 subunit and GABARAP (Kawaguchi and Hirano, 2007). CaMKII plays other critical roles in GABAergic plasticity including promoting receptor surface levels (Wang et al., 1995; Marsden et al., 2007, 2010; Saliba et al., 2012) and recruitment of the synaptic scaffold protein gephyrin, while reducing GABAₐR lateral diffusion (Petriti et al., 2014).

Internalization
Non-synaptic GABAₐRs on the cell surface are capable of undergoing internalization (Bogdanov et al., 2006), a fundamental cellular process that regulates receptor signaling and function (Figure 2). GABAₐR internalization is primarily clathrin-mediated in concert with GTPase dynamin activity and the adaptor protein AP2 complex (Kittler et al., 2000), although clathrin-independent GABAₐR endocytosis has been described (Cinar and Barnes, 2001; Rowland et al., 2006). AP2 interacts with the ICD of GABAₐR β subunits and the extrasynaptic δ subunit in a phospho-dependent manner (McDonald et al., 1998; Brandon et al., 2002, 2003; Herring et al., 2005; Kittler et al., 2005; Smith et al., 2008; Gonzalez et al., 2012; Smith et al., 2012). The γ2 subunit also contains two AP2 interaction domains on its ICD, a 12 basic amino acid region and a classical YGYECL motif (Smith et al., 2008) (Figure 1C). Phosphorylation at Y365/367 residues within the YGYECL motif by the non-receptor tyrosine-protein kinases...
Fyn and Src family kinases (Moss et al., 1995; Brandon et al., 2001; Jurd et al., 2010) reduces AP2 binding, as does mutation of Y3657F to phenylalanine (Kittler et al., 2008; Tretter et al., 2009). Homozygous tyrosine to phenylalanine (Y3657F) knock-in mice are developmentally lethal, suggesting phosphoregulation of these residues is critical for GABA$_\gamma$R function or trafficking in vivo. Heterozygous Y3657F knock-in mutant mice show inhibition of AP2 binding to the $\gamma$2 subunit, surface and synaptic accumulation of receptors and ultimately spatial memory deficits (Tretter et al., 2009). Further investigation revealed that brain-derived neurotrophic factor (BDNF) enhances Y3657F phosphorylation and stabilizes $\gamma$2-containing GABA$_\gamma$AR, consistent with heterozygous Y3657F mice showing an anti-depressant phenotype in the forced swim task and tail-suspension test and increased neurogenesis effects that are resistant to further enhancement by BDNF (Vithlani et al., 2013).

GABA$_\gamma$AR endocytosis can be increased by stimuli of opposite polarities, either excitotoxic protocols such as in vitro seizure (Goodkin et al., 2005, 2008; Naylor et al., 2005; Lorenz-Guertin et al., 2017) and oxygen-glucose deprivation (OGD) (Arancibia-Carcamo et al., 2009), or by prolonged inhibition with agonist exposure (Chaumont et al., 2013; Gutierrez et al., 2014). Internalization is in part regulated by phosophatase activity under these conditions. For example, inhibition of CaN or the serine/threonine protein phosphatase 1 (PP1) and 2A (PP2A) reverses a status epileptics induced decrease in surface $\gamma$2-GABA$_\gamma$ARs and mIPSC amplitude (Joshi et al., 2015). Importantly, genetic GABA$_\gamma$AR mutants also affect intracellular trafficking. For instance, the $\gamma$2 R82Q (numbering without signal peptide R43Q) mutation linked to childhood absence epilepsy and febrile seizures (FS) showed increased basal receptor endocytosis rates relative to wild-type (Chaumont et al., 2013). In summary, endogenous signaling pathways, pharmacological treatments, and pathological stimuli or genetic variation can modulate GABA$_\gamma$AR endocytosis networks [kinase and phosphatase regulation reviewed in Lorenz-Guertin and Jacob (2017)].

Recycling/Lysosomal Degradation

Internalized GABA$_\gamma$ARs can either be recycled back to the cell surface or targeted for degradation at lysosomes (Figure 2) (Kittler et al., 2004; Arancibia-Carcamo et al., 2009). Interaction of the integral membrane protein calcium-modulating cyclophilin ligand (CAML) with the $\gamma$2 subunit cytoplasmic and fourth transmembrane domain regions promotes forward trafficking and recycling (Yuan et al., 2008). Neurons lacking CAML demonstrate diminished recycling of endocytosed GABA$_\gamma$ARs and decreased inhibition strength. Broad PKC activity is implicated as a negative regulator of GABA$_\gamma$R recycling activity following internalization (Connolly et al., 1999). 5-HT2 serotonergic negative modulation of GABA$_\gamma$R currents is also thought to occur through a PKC-RACK1 (receptor for activated C kinase) mechanism (Feng et al., 2001).

Synaptic receptors destined for degradation undergo ubiquitination of 7 lysine residues within the ICD of the $\gamma$2 subunit (Figure 1C) (Arancibia-Carcamo et al., 2009). Lysine to arginine (K7R) mutation at these ubiquitination sites diminishes late endosome targeting of receptors in heterologous cells, and reduces loss of surface receptor clusters following OGD treatment (Arancibia-Carcamo et al., 2009). The ring finger protein 34 (RNF34) E3 ligase directly binds the $\gamma$2 ICD, co-immunoprecipitates with $\gamma$2 in vivo and can be identified at inhibitory synapses (Figure 2) (Jin et al., 2014). Interestingly, the short 14 amino acid motif in the $\gamma$2 ICD sufficient for RNF34 binding is identical to the GODZ binding region (Figure 1C), and is also highly conserved among the $\gamma$ subunits. $\gamma$2-GABA$_\gamma$AR degradation is accelerated upon overexpression of RNF34 resulting in smaller GABA$_\gamma$AR synaptic clusters and diminished inhibitory current strength. Proteosomal and lysosomal inhibitor experiments suggest RNF34 ubiquitination of $\gamma$2 contributes to degradation by both of these pathways in HEK cells. Notably, co-expression of RNF34 with the $\gamma$2 ubiquitin resistant K7R mutant did not inhibit degradation of this subunit. On the contrary, additional lysine mutations (K8R, K9R, K10R) were able to prevent downregulation of $\gamma$2 by RNF34, suggesting these residues may be important for ubiquitination-degradation.

Only a handful of stimuli clearly induce lysosomal degradation of GABA$_\gamma$ARs, likely due to the receptor's crucial role in maintaining neuronal inhibition and the tight regulation of receptor surface levels that must therefore occur. Our lab previously found 24 h benzodiazepine treatment in cultured hippocampal neurons enhances lysosomal-mediated degradation of $\alpha$2-containing receptors (Jacob et al., 2012). More recently, we identified that a GABA$_\gamma$R antagonist bicuculline acute seizure model also induces lysosomal targeting of surface GABA$_\gamma$ARs in cultured cortical neurons (Lorenz-Guertin et al., 2017). It is likely that stimulus specific subunit ubiquitination patterns ultimately dictate receptor fate. This remains a highly understudied area of research in GABA$_\gamma$AR trafficking.

Proteomics

The network of proteins governing inhibitory synapse clustering, trafficking, and plasticity are unresolved, as evidenced by three recent in vivo inhibitory synapse proteomic screenings utilizing either knock-in mice expressing GFP-tagged $\alpha$2 subunit (Nakamura Y. et al., 2016), adeno-associated viral (AAV) expression of fusion proteins including gephyrin (Uezu et al., 2016), or mice expressing a Thy1-His6-Flag-YFP-$\gamma$2 subunit transgene (Ge et al., 2018). Initial analysis from these experiments has revealed novel inhibitory protein constituents including the metabotropic glutamate receptor subunit mGlur5, the DbI family GEF Ephexin, metabotropic GABA B receptor (GABA$_B$R) auxiliary subunit KCTD12, and inhibitory synaptic regulator protein 1 (InSyn1) (Nakamura Y. et al., 2016; Uezu et al., 2016). Most recently, tandem affinity purification proteomics revealed the critical GABA$_\gamma$R forward trafficking component CLPTM1, and two novel interactors including integral membrane protein 2C (ITM2C) and Golgi glycoprotein 1 (GLG1) (Ge et al., 2018). Considering new candidate interactor proteins are identified with slight
derivations in methodology (140 in Uezu et al., 2016; 149 in Nakamura Y. et al., 2016; 39 additional in Ge et al., 2018), future investigations will need to both confirm the validity and importance of these observed proteins in GABA<sub>R</sub> function and modulation.

**Genetic Knockdown and Knockout of γ2 in Rodents**

Due to the fundamental importance of γ2 GABA<sub>R</sub> inhibition in the CNS, embryonic KO animals die within days of birth (Gunther et al., 1995). Developmentally delayed KO of γ2 using a CaMKIICre transgene expression system results in mice who are phenotypically normal 3 weeks post-natal, but by week 4 exhibit a rapid decline in health including epileptic episodes and eventually death (Schweizer et al., 2003). A large drop in gephyrin immunoreactivity also occurs coincident with loss of γ2 expression without changing GABA<sub>A</sub>ergic presynaptic innervation as measured by vesicular inhibitory amino acid transporter (VIAAT) levels.

Partial KD of brain wide γ2 levels results in impaired behavior including an enhanced anxious-depressive phenotype (Crestani et al., 1999; Chandra et al., 2005; Earnheart et al., 2007; Shen et al., 2010). In addition, heterozygous γ2<sup>+/−</sup> mice show defective spine maturation and synaptogenesis (Ren et al., 2015). Ablating forebrain γ2 expression in embryonic glutamatergic neurons using homoyzygous EMX1Cre-induced inactivation also recapitulated the depressive-anxiety phenotype and reduced hippocampal neurogenesis similar to total heterozygous γ2 KO mice (Earnheart et al., 2007). In contrast, KD of γ2 in neurons at post-natal day 13/14 did not affect hippocampal neurogenesis, but anxiety- and depressive-like behavior still formed (Shen et al., 2012). Numerous studies have examined brain-region or cell-type specific γ2 KD or KO describing circuit specific roles that will not be discussed here (Buhr et al., 1997; Wingrove et al., 1997; Wulff et al., 2007, 2009; Lee et al., 2010; Leppa et al., 2011, 2016; Zecharia et al., 2012; Stojakovic et al., 2018).

Homozygous deletion of γ2L in mice results in near complete replacement with γ2S subunit (Homanics et al., 1999). When examining γ2S isoform specific ablation, in vitro findings (refer to earlier discussion in Synaptic Accumulation and Functional Regulation) would suggest GABA<sub>A</sub>R incorporating γ2L vs. γ2S would incur distinct changes in functional and pharmacological properties of GABA<sub>A</sub>R. Yet, this isoform switch did not result in changed responsiveness to ethanol in behavioral or electrophysiology experiments, although a mild increase in anxiety was observed (Homanics et al., 1999). Interestingly, the γ2L<sup>−/−</sup> mice did show a modest increase in behavioral sensitivity and GABA<sub>A</sub>R affinity for benzodiazepine agonists (Quinlan et al., 2000). Isoform switching of γ2 in vivo has been described to occur in response to certain cues such as chronic intermittent ethanol administration in rats (Petrie et al., 2001; Cagetti et al., 2003) and in schizophrenic brains of humans (Huntsman et al., 1998). The relevance of γ2 isoform switching and predominance to pathophysiology in vivo remains poorly understood.

**HUMAN GENETIC VARIATION OF γ2 AND PATHOLOGICAL IMPLICATIONS**

Pathology Arises From γ2 Genetic Anomalies in Humans

Amongst all the subunit genes, mutations in GABRG2 encoding the γ2 subunit are most commonly linked to epileptogenesis (Macdonald et al., 2012). Indeed, heterozygous γ2 R82Q mutant mice were one of the first in vivo models for childhood absence epilepsy, recapitulating a familial mutation phenotype including onset, behavior, and treatment responsiveness (Tan et al., 2007). GABRG2 genetic anomalies including missense, nonsense, frameshift, splice-site, insertion and deletion mutations are associated with epilepsy phenotypes ranging from mild FS to moderate generalized tonic-clonic seizures or more severe disorders such as Dravet syndrome (DS) or epileptic encephalopathies (further information found in Kang and Macdonald, 2016). In order to bridge the gap between known γ2 trafficking mechanisms, identified protein interaction sites and human pathology, we examined γ2 subunit genetic variation using the Genome Aggregation Database (gnomAD) (Lek et al., 2016), a dataset of exome sequence data from 123,136 individuals and whole genome sequencing from 15,496 unrelated individuals without any severe pediatric disease and their first-degree relatives. We focused specifically on synonymous (codon substitutions result in no amino acid sequence change) and non-synonymous (alter amino acid sequence) mutations. Although synonymous codon changes were previously labeled as “silent” mutations and thought to have limited consequences, recent data indicates these may also impact function and contribute to disease through effects on cis-regulatory elements, mRNA structure, and protein expression. Non-synonymous mutations that result in a stop codon are referred to as nonsense mutations whereas missense mutations result in the exchange of one amino acid for another. Non-synonymous mutations may affect structural and functional properties and be associated with a disease condition; however, others may be functionally neutral and not related to a disease phenotype. Protein domains which show significant diversity in mutations identify regions of genetic flexibility, while regions with low allele frequency events (standard threshold of 0.1%) identify potentially pathogenic mutations that are not evolutionarily favored (Dudley et al., 2012). In the γ2S isoform, we identified and plotted the distribution of 104 synonymous and 122 non-synonymous missense variants (Figure 3A) (Jay and Brouwer, 2016). Five additional non-synonymous variants were found in the γ2L specific sequence (LLRMFSFK: L377R, R379W, R379Q, F381L, S382C), while no synonymous variants were identified (Figure 3A). Of note, there is a third putative γ2 isoform which appears conserved in humans and primates including the great apes and old world monkeys but absent in rodents that was not evaluated here for human genetic variation (ENST00000414552, Y211 is substituted by W, followed by 40 additional amino acids in the N-terminal extracellular domain). Overall, the latter half of the ECD, TM and linker regions showed low levels of missense variation when compared to synonymous variation (Figure 3A).
We next turned to the patient epilepsy disease case variants to determine if these are over-represented in similar regions. Disease case variants were gathered from National Center for Biotechnical Information (NCBI), ClinVar, and Human Gene Mutation Databases (HGMD), yielding a total of 49 pathogenic or likely pathogenic mutations including 25 missense, 11 nonsense, 9 frameshift, and 4 intron splice variants. The distribution of the 36 epilepsy-related missense and nonsense mutations was mapped across the γ2 subunit protein domains (Figure 3B). The 11 γ2 nonsense variants resulted in early stop
codons (X) throughout the following domains: (1) ECD = Q40X, L91X, R136X, Y180X, G273X; (2) M1 = Y274X (2 unique stop codon mutant variants), W295X; (3) ICD = Q390X, R425X, W429X. The 25 γ2 subunit missense mutations showed wider distribution throughout the ECD, M1-4, M2-M3 linker and ICD regions. Comparison of the disease-associated and gnomAD missense variants identified significantly greater percentages of epilepsy related variants in the M2 and M2-M3 linker regions (Table 1). In contrast, signal peptide missense mutations were not found and ICD missense mutations were less prevalent in epilepsy patients (Table 1).

In the field of medical genomics, identification of potentially pathological mutations is a significant challenge, prompting the development of multiple bioinformatics methods to assess non-synonymous variants. We used the sequence homology-based genetic analysis bioinformatics programs PROVEAN (Protein Variation Effect Analyzer) and SIFT (Sorting Intolerant from Tolerant) to assess non-synonymous variants in the gnomAD population and predict the effects on γ2 subunit biological function. Interestingly, 35 of the 122 non-synonymous gnomAD variants were also predicted to be putatively damaging/deleterious by both of the two bioinformatics tools (scoring agreement at 81.9%, Figure 3A, orange colored variants). Neutral scored non-synonymous variants included S386P and T388A (aka S355 and T357 phosphorylation sites, Figure 1C). None of the γ2L isoform missense variants were predicted by PROVEAN as damaging, although S382C (aka S343, the PKC/CaMKII phosphorylation site, see earlier Synaptic Accumulation and Functional Regulation, Figure 1C) was predicted as possibly damaging by SIFT. Among the gnomAD population six variants were identified that overlapped the epilepsy patient missense group (L57F, N79S, M199V, R177Q, A334T, R363Q): three were predicted as deleterious (N79S, M199V, A334T) and 3 as neutral (L57F, R177Q, R363Q). PROVEAN and SIFT bioinformatics analysis of the 25 epilepsy patient missense variants showed four as neutral (L57F, A106T, L307V and R363Q), two had conflicting predictions (L74V, R304K), and all others were scored as damaging. As the gnomAD population is relatively free from significant clinical disorders, this implies masking by epistatic genetic interactions, consistent with phenotypic variability seen in epilepsy patients and animal epilepsy models. In addition, although in silico prediction tools show overall robust performance, particularly when software are used in combination (Leong et al., 2015; Masica and Karchin, 2016), this suggests pathological variants can be missed. Improving clinically admissible predictions from these in silico tools is a current high priority focus in medical bioinformatics (Masica and Karchin, 2016; Ernst et al., 2018). To expand our insight into the cellular pathology underlying the thirty-six patient cases, we next cross-examined database information (NCBI, ClinVar, HGMD) and the current literature for disease phenotypic and cellular study based analysis.

**Patient Epilepsy Phenotypes**

The most common patient phenotypes associated with nonsense and missense mutations ranged in severity and included FS, generalized tonic-clonic seizures (GTCS), GTCS with FS, genetic epilepsy with FS (GEFS), genetic epilepsy (GE), DS, and epileptic encephalopathy with severe global developmental delays (EEDD). FS are a relatively mild pathology which occur in the presence of fevers and display tonic-clonic seizure activity in individuals between 6 months and 5 years of age (Boillot et al., 2015). FS which have prolonged episode duration and occur past 6 years of age are termed FS+ and are generally associated with increased risk for developing epilepsy later in life. Moderate forms of epilepsy include GTCS and GE both with and without FS, where FS can co-occur with persistent seizure episodes past childhood and can present intense seizure activity more commonly known as a “grand mal” seizure as in the case of GTCS (Johnston et al., 2014; Wang et al., 2016; Fisher et al., 2017). The most severe phenotypes reported are DS and EEDD. In particular, DS is subset of epileptic encephalopathy and is characterized by a wide range of seizure type activity as well as psychomotor development delays, ataxia and hyperkinesis emerging between the ages of 1–4 (Ishii et al., 2014; Fisher et al., 2017). In contrast, EEDD have broader phenotypic manifestations and deficits as a result of global neurodevelopmental impairments with treatment-resistant seizures (Shen et al., 2017). Less common reported patient phenotypes included myoclonic epilepsy, absence seizures, complex partial seizures, tonic infantile spasms, tonic seizures, Rolandic epilepsy, and ASD with learning difficulties. In vitro studies have been invaluable in gaining in depth understanding of etiology, cellular pathology, and functional effects of these epilepsy patient variants.

**γ2 Subunit Disease Case Analysis**

In vitro studies on 17 of the γ2 pathogenic variants have revealed reduced surface expression in 15 cases, in part resulting from ER retention and trafficking defects (Table 2). The severe disease DS epilepsy phenotype is associated with three nonsense mutations (Q40X, R136X, Q390X) and one missense (P302L) mutation (Table 2). The early occurrence of Q40X and R136X within the ECD resulted in premature termination codons (PTCs) and mRNA degradation via nonsense mediated mRNA decay (NMD) with decreased γ2 protein levels. The introduction of upstream PTCs limited the availability of trafficable γ2, diminished overall receptor surface expression and synaptic localization and resulted in significant GABAAergic deficits (Ishii et al., 2014). Conversely, the Q390X (previously known as Q351X) mutation occurs in the ICD and escapes NMD but is instead subject to ubiquitin-proteasome degradation (Kang et al., 2013). In vitro experiments found Q390X to have comparable mRNA levels to other late sequence nonsense mutations but dissimilar protein expression due to different degradation rates. Q390X displayed a substantially longer half-life as compared to wild-type γ2 and other nonsense mutant subunits in addition to an increased ability to oligomerize with and sequester wild-type α and β subunits. This alternative disruption in receptor trafficking provides evidence that expressed non-functional truncated subunits may be modifiers of epilepsy phenotype severity. Interestingly, P302L was the only missense mutation reported in...
Table 1 Genetic variation across GABRG2 domains.

| Region    | Residues | GnomAD missense | Disease-associated missense | p-value |
|-----------|----------|-----------------|-----------------------------|---------|
| Signal peptide | 1–39     | 21              | 17.21                       | 0.00    | *0.025 |
| ECD       | 40–273   | 53              | 43.44                       | 12      | 0.8255 |
| M1        | 274–296  | 3               | 2.48                        | 3       | 0.0016 |
| M1–M2 loop | 297–299  | 0               | 0.00                        | 0.00    | 1      |
| M2        | 300–325  | 2               | 1.64                        | 3       | 12.00  | *0.0348|
| M2–M3 loop | 326–333  | 2               | 1.64                        | 3       | 12.00  | *0.0348|
| M3        | 334–356  | 3               | 2.46                        | 2       | 8.00   | 0.2006 |
| ICD       | 357–443  | 33              | 27.05                       | 1       | 4.00   | *0.0096|
| M4        | 444–466  | 5               | 4.10                        | 1       | 4.00   | 1      |
| C-Term    | 467      | 0               | 0.00                        | 0       | 0.00   | 1      |

Coordinates based on GABRG2 (GenBank NM_000816.3 transcript variant 2; y2S, Uniprot P18507). ECD, extracellular amino-terminal domain; M1–M4, transmembrane regions 1–4; ICD, intracellular domain; C-Term, carboxy-terminus. Fisher’s exact t-test p-values are reported; * denotes statistical significance.

Throughout the reviewed mutations, only two variants (L57F and N79S) deviated from a pathology associated with reduced γ2 containing GABAAR plasma membrane levels and were located in the ECD. L57F was present in an individual with GE and found to have normal surface and trafficking characteristics compared to wild-type γ2 receptors; however, altered current density properties and function were observed possibly due to minor structural perturbations in the α1-helix of the ECD (Hernandez et al., 2016). Comparatively, the N79S mutation was the sole occurrence of GTCS without co-occurring phenotypes and presented slight but significant impairments in plasma membrane levels and peak current amplitude (Huang et al., 2014) suggesting it is more of a susceptibility variant as opposed to an epilepsy mutation (Shi et al., 2010; Migita et al., 2013; Huang et al., 2014). Moreover, the resilience of the ECD is further supported by R82Q (previously known as R43Q), a well characterized missense mutation associated with mild phenotypic manifestations like FS and absence seizures with trafficking deficient pathologies (Macdonald et al., 2012). Overall, the 13 frameshift and intron splice variant mutations analyzed were associated with mild phenotypes, though further studies are needed to elucidate their pathological mechanisms (Table 3). However, frameshift mutations within the ICD (E402Dfs*3 generating a stop codon at Y404X critical Src/Fyn phospho site discussed earlier; and S443delC resulting in an altered and elongated carboxy terminus with +50 novel AA) were associated with more moderate-severe phenotypes like GTCS and GEFS+ underscoring the importance for intracellular regulation via the ICD (Macdonald et al., 2012).

In summary, both deficits in GABAAR surface trafficking and the functional role of specific γ2 subunit regions are critical factors modulating phenotypic outcome, with some missense mutations resulting in phenotypes as severe as nonsense mutations. Furthermore, expressed non-functional truncated subunits may be correlated with more severe manifestations and be modifiers of disease phenotypes. Disease case variants in the pore lining M2 region showed particularly severe phenotypes, consistent with the reduced genetic variation in this region in a patient with DS (Hernandez et al., 2017). Of note, this mutation resides in M2 and contributes to the formation of the ion channel pore which likely explains its severe phenotype. This is supported by P302L mutant electrophysiological studies and structural modeling which suggests a shift in pore activity resulting in slow activation, low conductance states, and fast desensitization of GABAAR (Hernandez et al., 2017). In contrast, all six cases of EEEDD were found in patients with missense mutations (A106T, I107T, P282S, R323W, R323Q, F343L) dispersed throughout structural domains (ECD, M1 and M2) and exhibited additional epileptic phenotypes such as GTCS, GEFS, and tonic seizures (Shen et al., 2017). In fact, the I107T mutation is located in the ECD which typically tolerates missense mutations; however, this mutation was found to exhibit the most severe cellular pathologies as evidenced by relatively mild phenotypes; however, this mutation was found to exhibit the most severe cellular pathologies as compared to other disease variants emphasizing the need to further investigate these mutations and their ramifications on cellular processes.

The moderate epileptic phenotype GEFS without co-occurring conditions was observed in three cases with two missense (P83S and K328M) and one nonsense (W429X) variants reported with structural locations in the ECD, M2-M3 linker, and ICD, respectively (Table 2). P83S was found to reduce GABA-evoked whole cell currents mainly through a plasma membrane and trafficking-dependent manner (Lachance-Touchette et al., 2011; Huang et al., 2014; Bennett et al., 2017). In contrast, K328M (previously known as K289M) is found in the short extracellular loop between the M2-M3 regions and was found to increase receptor deactivation, implicating this region in receptor kinetic properties (Macdonald et al., 2012). Conversely, W429X displayed less drastic protein degradation and subunit oligomerization pathologies compared to the previously discussed DS variant Q390X (Wang et al., 2016). The later downstream incidence of W429X combined with slightly higher surface expression compared to Q390X may explain the milder epilepsy phenotype (Sun et al., 2008; Macdonald et al., 2012; Kang et al., 2013; Wang et al., 2016).
| Region | Variant | Trafficking | ER retention | Surface expression | Cell current | Febrie seizures | Generalized tonic-clonic seizures | Genetic epilepsy | Dravet syndrome | Epileptic encephalopathy | Other |
|--------|---------|-------------|--------------|-------------------|-------------|----------------|-------------------------------|----------------|----------------|------------------------|-------|
| ECD    | Q40X    | ↓↓          | ↑            | ↓↓                | ↓↓          |                | ✓                            |                |                |                        |       |
| ECD    | L57F    | –           | ✓            | –                 | ↓↓          |                | ✓                            | ✓              |                |                        |       |
| ECD    | N79S    | ↓           | –            | ↓                 | ↓           | ✓              |                |                |                |                        | ✓     |
| ECD    | P82Q    | ↓           | ↑            | ↓                 | ↓           | ✓              |                |                |                |                        | ✓     |
| ECD    | P83S    | ↓↓          | ↑            | ↓↓                | ↓↓          | ✓              | ✓                            |                |                |                        |       |
| ECD    | A106T   | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                |                |                |                        |       |
| ECD    | I107T   | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                | ✓              |                |                        |       |
| ECD    | Q257F   | ↓↓          | ↑            | ↓                 | ↓           | ✓              |                | ✓              |                | ✓                    |       |
| M1     | P282S   | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                |                |                |                        |       |
| M2     | P302L   | –           | ↔            | ↓                 | ↓           | ✓              |                |                |                | ✓                    |       |
| M2-M3 loop | K328M | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                |                |                | ✓                    |       |
| M3     | F343L   | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                |                |                | ✓                    | ✓     |
| ICD    | Q390X   | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                | ✓              |                | ✓                    |       |
| ICD    | W4219X  | ↓↓          | ↑            | ↓                 | ↓↓          | ✓              |                |                |                | ✓                    | ✓     |

Variants are organized by nucleotide sequence position, and variants ending in ‘X’ are nonsense mutations with all others being missense mutations. Other epileptic or developmental phenotypes include absence seizures, complex partial seizures, severe global developmental delay, tonic infantile spasms, autism disorder with learning difficulties, Rolandic epilepsy, or epilepsy with myoclonic-astatic seizures; ECD, extracellular amino-terminal domain; M1–M3, transmembrane regions 1–3; ICD, intracellular domain; ↓↓, reduced; ↑, increased; ✓, observed; ✓, unknown; -, not affected/changed; ↓, slightly reduced; ↔, possibly.
### TABLE 3 | Patient frameshift mutations and intron splice variants associated or likely associated with various epilepsy phenotypes.

| Region            | Canonical sequence codon | Mutant sequence | Variant name/Aminoterminal domain | Mutation type | Phenotype(s)                                      | Function effect(s)                                                                 |
|-------------------|---------------------------|----------------|----------------------------------|---------------|-------------------------------------------------|----------------------------------------------------------------------------------|
| ECD               | ACT-CCA-AAA 58 59 60      | ACA-CAA-AAG    | P59Qfs*12                        | Frame shift   | Febrile Seizures, Tonic-Clonic Seizures         | Predicted to undergo NMD (Boillot et al., 2015).                                  |
| ECD               | TTT-GCG-CAA 117 118 119   | TTT-TGC-GCA    | A118Cfs*6                        | Frame shift   | Febrile Seizures                                 | Predicted to undergo NMD (Della Mina et al., 2015).                              |
| ECD               | AAA-GCT-GAT 57 58 59      | AAG-CTG-ATG    | A158Lfs*13                       | Frame shift   | Unknown                                         | Predicted to cause loss of normal protein function either through protein truncation or NMD. # |
| ECD               | CGA-GTG-CTC 177 178 179   | CAG-TGC-TCT    | R177Qfs*6                        | Frame shift   | Childhood Absence Epilepsy, Febrile Seizures    | Predicted to cause loss of normal protein function either through protein truncation or NMD. # |
| Intron 4          | CTT-AGG-TTG Int4 184      | CTG-AGG-TTG    | 549-3T > G                       | Intron Splice Variant | Unknown                                         | Abnormal gene splicing; in silico assessment predicts altered protein function (Reinthaler et al., 2019). |
| Intron 6          | TCC-GTG-AAG 256 Int6      | TCC-GGG-AAG    | IVS6 + 2T > G                    | Intron Splice Variant | Childhood Absence Epilepsy, Febrile Seizures    | Truncation; ER retention; undergo NMD; decreased surface γ2 subunit levels and GABA-evoked whole cell currents; and increased ER stress marker BIP (Kananura et al., 2002; Tian and Macdonald, 2012). |
| ECD               | GGA-GAT-TAT 257 258 259   | AGA-GAT-TAT    | 770-1G > A                       | Intron Splice Variant | Suspected to cause epilepsy                      | Predicted to cause abnormal gene splicing and undergo NMD or the production of an abnormal protein. # |
| M3                | GTT-TGT-TTC 341 342 343   | GTT-TTT-CAC    | C342Ffs*50                       | Frame shift   | Childhood Absence Epilepsy, Febrile Seizures    | Not anticipated to result in NMD but expected to result in a truncated protein. # |
| FproveIntron 8    | CAG-GCC-CCT Int8 377 378  | CGG-GCC-CCT    | 1129-2A > G                      | Intron Splice Variant | Childhood Absence Epilepsy, Febrile Seizures    | Not anticipated to undergo NMD, but likely alters RNA splicing and disrupts protein function. # |
| ICD               | ATT-CAA-GAG 397 398 399   | ATT-CCA-GAG    | Q398Rfs*4                        | Frame shift   | Unknown                                         | Predicted to cause protein truncation. #                                      |
| ICD               | GAA-GAG-TAC 402 403 404   | GAT-TCA-TGA    | E402Dfs*3                        | Frame shift   | Febrile Seizures, Temporal Lobe Encephalopathy, Generalized Tonic-Clonic Seizures, Focal seizures | Predicted to cause protein truncation (Boillot et al., 2015). # |
| ICD               | TCC-TAT-GCT 443 444 445   | TCT-ATG-TCT    | S443delC                         | Frame shift   | Genetic Epilepsy with Febrile Seizures Plus     | Produced elongated peptide with 50 novel amino acids compared to γ2S; trafficking impairments, ER retention, decreased surface expression and whole cell currents (Tian et al., 2013). |
| M4                | GTC-TCC-TAC 462 463 464   | TCT-CCT-ACC    | V462Sfs*33                       | Frame shift   | Febrile Seizures                                 | Predicted to escape NMD and produce elongated peptide with 32 novel amino acids as compared to γ2S (Boillot et al., 2015). # |

Patient variants are ordered by nucleotide sequence position of GABRG2. Nucleotides deleted (red) and inserted (green) for each variant are noted. ECD, extracellular amino-terminal domain; M3-M4, transmembrane regions 3-4; ICD, intracellular domain; NMD, nonsense-mediated mRNA decay; introduction of downstream premature stop codon following specified number of codons (*); predicted function from GeneDX (#).
gnomAD non-synonymous variants. Clearly, *in vitro* studies of recombinant receptor trafficking, electrophysiology and assembly have provided important insight into the underlying cellular pathology and functional effects of these epilepsy patient variants. Greater understanding of the consequences of γ2 genetic variation, both for revealing disease mechanisms and for GABA<sub>A</sub>R synaptic plasticity will be gained through application of innovative imaging methods in the neuronal context.

**LOOKING FORWARD: IMAGING ADVANCES**

Advancing imaging techniques are providing critical insight into GABA<sub>A</sub>R trafficking extending beyond basic endo/exocytic trafficking of receptors. Live-cell imaging using pH-sensitive GFP (pHluorin) tagged GABA<sub>A</sub>Rs subunits and fluorescence recovery after photobleaching (FRAP) experiments first identified GABA<sub>A</sub>R synaptic retention, limiting diffusion at synaptic release sites, and the crucial role of gephyrin in this process (Jacob et al., 2005). Receptor subunits with pHluorin tags have further described GABA<sub>A</sub>R surface levels and lysosomal degradation (Jacob et al., 2012; Lorenz-Guértin et al., 2017) and novel exocytic machinery and insertion sites of receptors (Gu et al., 2016). The pHluorin-FRAP technique is often performed in addition to the newer workhorse of diffusion studies, quantum dot (QD) single-particle tracking. QD studies have revealed precise quantitative properties of synaptic and extrasynaptic GABA<sub>A</sub>R diffusion during baseline conditions (Renner et al., 2012), excitatory stimulation (including iLTP) (Bannai et al., 2009, 2015; Muir et al., 2010; Niwa et al., 2012; Muir and Kittler, 2014; Petrini et al., 2014), GABA<sub>A</sub>R agonist and/or drug treatment (Gouzer et al., 2014; Levi et al., 2015; de Luca et al., 2017), GABA<sub>B</sub> receptor activation (Gerrow and Triller, 2014), purinergic (P2X2 receptor) activation (Shrivastava et al., 2011), and changes in gephyrin or radixin phosphorylation (Hausrat et al., 2015; Battaglia et al., 2018). Receptor functional regulation by changes in surface diffusion, perhaps completely independent of changes in surface levels, represents a paradigm shift in our basic understanding of synaptic plasticity. Indeed current studies of human genetic variants in recombinant systems are unlikely to detect these fundamentally important properties due to lack of a neuronal context, the appropriate GABA<sub>A</sub>R subunit complement, interacting proteins, and general overexpression problems. For example, QD neuronal studies of the γ2 K328M disease variant revealed an additional phenotype of enhanced temperature sensitive receptor diffusion, likely contributing to the FS pathology in patients (Bouthour et al., 2012).

To address multiple trafficking questions within a single assay, our group recently engineered a GABA<sub>A</sub>R γ2 subunit dual fluorescent sensor encoding a pHluorin tag and a fluorogen-activating peptide (FAP) (γ2<sup>3H</sup>FAP) (Lorenz-Guértin et al., 2017). FAPs are antibody single chain variable fragments characterized to selectively bind inorganic dyes with high specificity and affinity (Szent-Györgyi et al., 2008). The dyes are non-fluorescent until bound by a FAP and individual dyes have unique characteristics including cell permeability, pH-sensitivity, fluorescent properties, and *in vivo* administration capability (Fisher et al., 2010; Grover et al., 2012; Saunders et al., 2012; Zhang et al., 2015; He et al., 2016). We have used the FAP-dye system in neurons to selectively examine cell surface GABA<sub>A</sub>Rs undergoing internalization, early endosomal accumulation and targeting to late endosomes/lysosomes via confocal live-imaging (Lorenz-Guértin et al., 2017). Pulse-labeling γ2<sup>3H</sup> FAP with cell impermeable dye allows for detection of surface receptor turnover rates independent of a change in total GABA<sub>A</sub>R surface levels, as we demonstrated using a mild seizure protocol. As more GABA<sub>A</sub>Rs subunits are engineered to express the FAP tag, and additional unique dyes are synthesized to address specific experimental questions, the utility of this imaging approach continues to grow.

Other innovative imaging approaches advancing our ability to detect changes in GABA<sub>A</sub>R synaptic plasticity include optogenetic toolkits for controlling GABA<sub>A</sub>R activity (Lin et al., 2014, 2015), spatially regulated GABA activation using two-photon photolysis (Oh et al., 2016), proximity ligation assays to measure endogenous protein interaction (Smith et al., 2014; Tseng et al., 2015; Ghosh et al., 2016), and super-resolution imaging and other fluorescent tools to examine inhibitory gephyrin scaffolding (Gross et al., 2013, 2016; Sigal et al., 2015; Maric et al., 2017; Pennacchietti et al., 2017). Fluorescence resonance energy transfer (FRET) techniques have been limitedly applied to studying GABA<sub>A</sub>R trafficking or receptor subunit composition (Ding et al., 2010; Shrivastava et al., 2011), collectively suggesting imaging techniques will be a rich resource of novel GABA<sub>A</sub>R knowledge.

**CONCLUSION**

In summary, we live in an unprecedented time for understanding human disease pathology and neurodevelopment through integration of “big data” on human genetic variation and protein interaction networks/interactomes, in combination with high resolution live-imaging approaches. Future efforts to resolve GABA<sub>A</sub>R pathologies will benefit from connecting genetic variants to their cellular mechanisms of pathology within the complexity of neuronal signaling. Importantly, increased understanding of surface and intracellular pool regulated trafficking of GABA<sub>A</sub>R will provide mechanisms to treat overall reduced receptor levels in various disease states. Future treatment of genetic epilepsy syndromes are likely to involve CRISPR-Cas9 gene editing (Ma et al., 2017), RNA focused REPAIR editing approaches, or application of improved drugs that act as chaperones to promote receptor trafficking. The new imaging based methods described here are particularly likely to show high utility in both identifying cellular pathology of human GABA<sub>A</sub>R genetic variants and for drug screening efforts in a neuronal context.
MATERIALS AND METHODS

Data Mining of GABRG2 Genetic Variation

The prevalence of γ2 subunit non-synonymous and synonymous variations in gnomAD, currently a dataset of exome sequence data from 123,136 individuals and whole genome sequencing from 15,496 unrelated individuals, was assessed and restricted to those meeting the “PASS” quality threshold (Lek et al., 2016). Individuals known to be affected by severe pediatric disease are not contained in this data set, or their first-degree relatives. Next “pathogenic” and “likely pathogenic” patient case variants not present in the gnomAD dataset were investigated in National Center for Biotechnical Information variation viewer (NCBIv), ClinVar, and Human Gene Mutation Databases (HGMD) utilizing the following search parameters: GRCh37.p13 annotation release 105 assembly and NM_000816.3 (transcript variant 2, γ2S). The search in NCBIv identified 17 variants (accessed January 2018). The ClinVar search (accessed February 2018) confirmed 16/17 candidate variants with the outlier (R323W) having been newly identified in the literature (Shen et al., 2017). In addition to those confirmed, the ClinVar investigation produced 10 additional mutations. Some variants identified in ClinVar had associated predicted functions (submitted by GeneDX genetics company)3. Finally, HGMD (hgmd2018.1; accessed March 2018) interrogation uncovered 22 disease-causing mutations that were absent from NCBIv and ClinVar inquiries4. Using these candidate case variants and their associated database information, the current literature was evaluated for disease phenotypic and cellular study based implications yielding a total of 49 pathogenic or likely pathogenic mutations including 25 missense, 11 nonsense, 9 frameshift, and 4 intron splice variants. We used lollipops-v.1.3.1 software (Jay and Brouwer, 2016) to plot the distribution of synonymous, non-synonymous and disease case mutations in GABRG2 along a linear γ2S assembly (P18507, ENST00000361925) and a linear segment representation of the additional eight encoded amino acids within the ICD in the γ2L isoform (P18507-2, ENST00000356592). The missense and nonsense disease case variants studied at the cellular trafficking level were included in Table 2. The frameshift and intron splice variants were annotated in Table 3.

WEB RESOURCES

- gnomAD, http://gnomad.broadinstitute.org/
- ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/
- Human Gene Mutation Database, http://www.hgmd.org/
- Lollipops v.1.3.1, https://github.com/pbnjay/lollipops/releases
- UniProt, http://www.uniprot.org/

AUTHOR CONTRIBUTIONS

JL-G and TJ wrote and edited the sections “γ2 Subunit Trafficking and Interactors” and “Looking Forward: Imaging Advances.” MB and TJ analyzed, wrote, and prepared the section “Human Genetic Variation of γ2 and Pathological Implications” and associated tables. TJ prepared all the figures. MB prepared all the tables.

FUNDING

This work was generously funded by T32GM008424 and R56MH114908-01, the William C. deGroat Neuropharmacology Departmental Fellowship, and Pharmacology and Chemical Biology Startup Funds.

REFERENCES

Allred, M. J., Mulder-Rosi, J., Lingenfelter, S. E., Chen, G., and Luscher, B. (2005). Distinct gamma2 subunit domains mediate clustering and synaptic function of postsynaptic GABAA receptors and gephyrin. J. Neurosci. 25, 594–603. doi: 10.1523/jneurosci.0054-2005

Arancibia-Carcamo, I. L., Yuen, E. Y., Muir, J., Lumb, M. J., Michels, G., Saliba, R. S., et al. (2009). Ubiquitin-dependent lysosomal targeting of GABA(A) receptors regulates neuronal inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 17552–17557. doi: 10.1073/pnas.0905502

Bannai, H., Levi, S., Schweizer, C., Inoue, T., Rauney, T., Racine, V., et al. (2009). Activity-dependent tuning of inhibitory neurotransmission based on GABAAR diffusion dynamics. Neuron 62, 670–682. doi: 10.1016/j.neuron.2009.04.023

Bannai, H., Niwa, F., Sherwood, M. W., Shrivastava, A. N., Arizono, M., Miyamoto, A., et al. (2015). Bidirectional control of synaptic GABAAR clustering by glutamate and calcium. Cell Rep. 13, 2768–2780. doi: 10.1016/j.celrep.2015.12.002

Bioinformatics Tools

PROVEAN (Protein Variation Effect Analyzer5 (Choi et al., 2012) and SIFT (Sorting Intolerant from Tolerant) algorithms (Hu and Ng, 2013) are bioinformatics tools which predict whether an amino acid substitution or indel (insertion or deletion) has an impact on a protein’s biological function using homology based genetic analysis. Currently PROVEAN provides scoring via both PROVEAN and SIFT algorithms. PROVEAN utilizes pairwise sequence alignment scores to generate pre-computed predictions at every amino acid position in all human and mouse protein sequences. Mutations are predicted to be deleterious or tolerant based on the prediction cutoff value of −2.5: scores smaller than −2.5 are considered deleterious. Similarly, SIFT predicts whether the amino acid substitution alter the protein function based on sequence homology and the physical properties of amino acids. The intolerant range of SIFT is ≤0.05 for predicted damaging/deleterious mutations and a score of >0.05 predicts the tolerant range.

WEB RESOURCES

1 http://gnomad.broadinstitute.org/transcript/ENST00000361925
2 https://www.ncbi.nlm.nih.gov/clinvar
3 https://www.genedx.com/
4 http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GABRG2
5 http://provean.jcvi.org

Author contributions statement

JL-G and TJ wrote and edited the sections “γ2 Subunit Trafficking and Interactors” and “Looking Forward: Imaging Advances.” MB and TJ analyzed, wrote, and prepared the section “Human Genetic Variation of γ2 and Pathological Implications” and associated tables. TJ prepared all the figures. MB prepared all the tables.

Funding

This work was generously funded by T32GM008424 and R56MH114908-01, the William C. deGroat Neuropharmacology Departmental Fellowship, and Pharmacology and Chemical Biology Startup Funds.

1 http://gnomad.broadinstitute.org/transcript/ENST00000361925
2 https://www.ncbi.nlm.nih.gov/clinvar
3 https://www.genedx.com/
4 http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GABRG2
5 http://provean.jcvi.org
Battaglia, S., Renner, M., Rousseau, M., and Come, E. (2018). Activity-dependent inhibitory synapse scaling is determined by gephyrin phosphorylation and subsequent regulation of GABAA receptor diffusion. *eNeuro*. doi: 10.1523/eneuro.0203-17.2017

Baulac, S., Huberfeld, G., Gourfinkel-An, L, Mitropoulou, G., Beranger, A., Prud'Homme, J. F., et al. (2001). First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. *Nat. Genet.* 28, 46–48. doi: 10.1038/ng8254

Bennett, C. A., Petrovski, S., Oliver, K. L., and Berkovic, S. F. (2017). ExACtly zero or once: a clinically helpful guide to assessing genetic variants in mild epilepsies. *NeuroX*. 3xe163. doi: 10.1211/NG.00000000000163

Bianchi, M. T., Song, L., Zhang, H., and Macdonald, R. L. (2002). Two different mechanisms of inhibition produced by GABA(A) receptor mutations linked to epilepsy in humans. *J. Neurosci.* 22, 5521–5527. doi: 10.1523/jneurosci.5521-02.2002

Boileau, A. J., Pearce, R. A., and Czajkowski, C. (2010). The short splice variant of a GABA(A) receptor subunit mutation [gamma 2(R43Q)] found in human epilepsies. *Epilepsia*. 51, 1214–1217. doi: 10.1111/j.1528-1167.2009.02451.x

Brandon, N., Jovanovic, J. N., Colledge, M., Kittler, J. T., Brandon, J. M., Connolly, C. N., Kittler, J. T., Thomas, P., Uren, J. M., Brandon, N. J., Smart, T. G., et al. (2012). A human mutation in Gabrg2 associated with generalized epilepsy alters the membrane dynamics of GABA(A) receptors. *Cereb. Cortex.* 22, 1542–1553. doi: 10.1093/cercor/bhr225

Brandon, N. J., Jovanovic, J. N., Delmas, P., Hill, J., Smart, T. G., and Moss, S. J. (2001). Constitutive tyrosine phosphorylation of the GABA(A) receptor gamma 2 subunit in rat brain. *Neuropharmacology.* 41, 745–752. doi: 10.1016/S0028-3908(01)00112-6

Brandon, N. J., Jovanovic, J. N., Collidge, M., Kittler, J. T., Brandon, J. M., Scott, J. D., et al. (2003). AKinase anchoring protein 79:150 facilitates the phosphorylation of GABA(A) receptors by cAMP-dependent protein kinase via selective interaction with receptor beta subunits. *Mol. Cell. Neurosci.* 22, 87–97. doi: 10.1016/S1044-7431(02)00017-9

Brandt, W., Bouthour, W., Leroy, F., Emmanuelli, C., Carnaud, M., Dahan, M., Poncer, J. C., et al. (2012). A human mutation in Gabrg2 associated with generalized epilepsy alters the membrane dynamics of GABA(A) receptors. *Cereb. Cortex.* 22, 1542–1553. doi: 10.1093/cercor/bhr225

Brennan, G. P., Jimenez-Mateos, E. M., McKiernan, R. C., McQuillan, J. M., Adler, S. A., Fuhrman, M. H., Waggoner, A. S., Bruchez, M. P., and Ernst, C., Hahnen, E., Engel, C., Nothnagel, M., Weber, J., Schmutzler, R. K., et al. (2010). Performance of in silico prediction tools for the classification of rare BRCAl2 missense variants in clinical diagnostics. *BMC Med. Genomics.* 11:35. doi: 10.1186/1471-2164-11-35

Borrelli, F., Tiso, D., Maestrini, E., Mazzini, M., Cianchi, G., and Galli, A. (2007). Effect of chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABA(A) receptors. *Mol. Pharmacol.* 63, 53–64. doi: 10.1124/mol.63.1.53

Carvill, G. L., Heawin, S. B., Yendle, S. C., McMahon, J. M., O'Roak, B. J., Cook, J., et al. (2013). Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nat. Genet.* 45, 825–830. doi: 10.1038/ng.2646

Chandra, D., Korpi, E. R., Miralles, C. P., De Blas, A. L., and Homanics, G. E. (2005). GABA(A) receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. *BMC Neurosci.* 6:30. doi: 10.1186/1471-2202-6-30

Chaumont, S., Andre, C., Perrais, D., Boue-Grabot, E., Taly, A., and Garret, M. (2013). Agonist-dependent endocytosis of gamma-aminobutyric acid type A (GABA(A)) receptors revealed by a gamma2(R43Q) epilepsy mutation. *J. Biol. Chem.* 288, 28254–28265. doi: 10.1074/jbc.M113.470807

Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., and Chan, A. P. (2012). Predicting the functional effect of amino acid substitutions and indels. *PLoS One.* 7:e46688. doi: 10.1371/journal.pone.0046688

Chou, W. H., Wang, D., McMahon, T., Qi, Z. H., Song, M., Zhang, C., et al. (2010). GABA receptor trafficking is regulated by protein kinase C epsilon and the N-ethylmaleimide-sensitive factor. *J. Neurosci.* 30, 13955–13965. doi: 10.1523/jneurosci.0270-10.2010

Cinar, H., and Barnes, E. M. Jr. (2001). Clathrin-independent endocytosis of GABA(A) receptors in HEK 293 cells. *Biochemistry*. 40, 1430–14306. doi: 10.1021/bi0101254

Connolly, C. N., Kittler, J. T., Thomas, P., Uren, J. M., Brandon, N. J., Smart, T. G., et al. (1999). Cell surface stability of gamma-aminobutyric acid type A receptors. Dependence on protein kinase C activity and subunit composition. *J. Biol. Chem.* 274, 36565–36572. doi: 10.1074/jbc.274.51.36565

Crestani, F., Lorez, M., Baer, K., Esirich, C., Benke, D., Laurent, J. P., et al. (1999). Decreased GABA(A) receptor clustering results in enhanced anxiety and a bias for threat cues. *Nat. Neurosci.* 2, 833–839. doi: 10.1038/12207

Cai, W., and Jarvis, B. K. (2013). Transgenic overexpression of 14-3-3 zeta protects from their extrasynaptic counterparts. *EMBO J*. 25, 4381–4389. doi: 10.1038/embj.2007.10309

Boillot, M., Baulac, S., Huberfeld, G., and de Gortari, F. (2007). GODZ-mediated palmitoylation of GABA(A) receptors revealed by a gamma2(R43Q) epilepsy mutation. *J. Biol. Chem.* 282, 28254–28265. doi: 10.1074/jbc.M113.470807

Cagetti, E., Liang, J., Spigelman, I., and Olsen, R. W. (2003). Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABA(A) receptors. *Mol. Pharmacol.* 63, 53–64. doi: 10.1124/mol.63.1.53

Della Mina, E., Ciccone, R., Brustia, F., Limongelli, I., Vetro, A., Nieus, T., Guazzi, S., et al. (2010). Synaptic lateral diffusion of GABA(A) receptors shapes inhibitory synaptic currents. *Neuron.* 95, 63–69.e5. doi: 10.1016/j.neuron.2010.06.022

Chen, G., et al. (2012). Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nat. Genet.* 45, 825–830. doi: 10.1038/ng.2646
against epilepsy: position paper of the ILAE commission for classification and terminology. *Epilepsia* 58, 522–530. doi: 10.1111/epi.13670

Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., et al. (2014). De novo mutations in schizophrenia implicate synaptic networks. *Nature* 506, 179–184. doi: 10.1038/nature12929

Frigier, G., Coussen, F., Giraud, M. F., Odessa, M. F., Emerit, M. B., Bouge, S., et al. (2007). A gamma 2(4R3Q) mutation, linked to epilepsy in humans, alters GABAA receptor assembly and modifies subunit composition on the cell surface. *J. Biol. Chem.* 282, 3819–3828. doi: 10.1074/jbc.M609102200

Ge, Y., Kang, Y., Cassidy, R. M., Moon, K. M., Lewis, R., Wong, R. O. I., et al. (2018). ClpTM1 limits forward trafficking of GABAA receptors to scale inhibitory synaptic strength. *Neuron* 97, 596–610.e8. doi: 10.1016/neuron.2017.12.038

Gerrow, K., and Triller, A. (2014). GABAA receptor subunit composition and competition at synapses are tuned by GABAB receptor activity. *Mol. Cell. Neurosci.* 60, 97–107. doi: 10.1016/j.mcneuron.2014.04.001

Ghosh, H., Auguardi, L., Battaglia, S., Simone Thirouin, Z., Zemoura, K., Messner, S., et al. (2016). Several posttranslational modifications act in concert to regulate gephyrin scaffolding and GABAergic transmission. *Nat. Commun.* 7:13365. doi: 10.1038/ncomms13365

Gonzalez, C., Moss, S. J., and Olsen, R. W. (2012). Ethanol promotes clathrin adaptor-mediated endocytosis via the intracellular domain of delta-containing GABAA receptors. *J. Neurosci.* 32, 17874–17881. doi: 10.1523/jneurosci.2535-12.2012

Goodkin, H. P., Joshi, S., Michedshihvili, Z., Brar, J., and Kapur, J. (2008). Subunit-specific trafficking of GABA(A) receptors during status epilepticus. *J. Neurosci.* 28, 2527–2538. doi: 10.1523/jneurosci.3426-07.2008

Goodkin, H. P., Yeh, J. L., and Kapur, J. (2005). Status epilepticus increases the intracellular accumulation of GABA(A) receptors. *J. Neurosci.* 25, 5511–5520. doi: 10.1523/jneurosci.0990-05.2005

Goto, H., Terunuma, M., Kanematsu, T., Misumi, Y., Moss, S. J., and Hirata, M. (2005). Direct interaction of N-ethylmaleimide-sensitive factor with GABA(A) receptor beta subunits. *Mol. Cell. Neurosci.* 30, 197–206. doi: 10.1016/j.mcn.2005.07.006

Gouzer, G., Specht, C. G., Allain, L., Shinoe, T., and Triller, A. (2014). Benzoazepine-dependent stabilization of GABA(A) receptors at synapses. *Mol. Cell. Neurosci.* 63, 101–113. doi: 10.1016/j.mcn.2014.10.004

Gross, G. S., Junge, J. A., Mora, R. J., Kwon, H. B., Olson, C. A., Takahashi, T. T., et al. (2013). Recombinant probes for visualizing endogenous synaptic proteins in living neurons. *Neuron* 78, 971–985. doi: 10.1016/neuron.2013.04.017

Hirose, S., Mitsudome, A., Okada, M., and Kaneko, S. (2005). Genetics of idiopathic epilepsies. *Epilepsia* 46, 38–43. doi: 10.1111/j.0013-9580.2005.46101.x

Homanics, G. E., Harrison, N. L., Quinlan, J. J., Krasowski, M. D., Rick, C. E., de Blas, A. L., et al. (1999). Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the gamma2 subunit of the gamma-aminobutyric acid type A receptor. *Neuropharmacology* 38, 253–265. doi: 10.1016/S0028-3908(98)01177-4

Huang, X., and Ng, P. C. (2013). SIFT Indel: predictions for the functional effects of amino acid insertions/deletions in proteins. *PLOS One* 8:e77940. doi: 10.1371/journal.pone.0077940

Huang, X., Hernandez, C. C., Hu, N., and Macdonald, R. L. (2014). Three epilepsy-associated GABRG2 missense mutations at the gamma2/beta-subunit interface disrupt GABAA receptor assembly and trafficking by similar mechanisms but to different extents. *Neurobiol. Dis.* 68, 167–179. doi: 10.1016/j.nbd.2014.04.015

Huang, X., Tian, M., Hernandez, C. C., Hu, N., and Macdonald, R. L. (2012). The GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome activated NMD and generated a truncated subunit that was partially rescued by aminoglycoside-induced stop codon read-through. *Neurobiol. Dis.* 48, 115–123. doi: 10.1016/j.nbd.2012.06.013

Huntsman, M. M., Tran, B. V., Potkin, S. G., Bunney, W. E., and Jones, E. G. (1998). Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyric acid type A receptor in prefrontal cortex of schizophrenics. *Proc. Natl. Acad. Sci. U.S.A.* 95, 15066–15071. doi: 10.1073/pnas.95.25.15066

Ishii, A., Kanaumi, T., Sotoda, M., Misumi, Y., Zhang, B., Kakinuma, N., et al. (2014). Association of nonsense mutation in GABRG2 with abnormal trafficking of GABAA receptors in severe epilepsy. *Epilepsy Res.* 108, 420–432. doi: 10.1016/j.eplepsyres.2013.12.005

Jacob, T. C., Bogdanov, Y. D., Magnus, C., Saliba, R. S., Kitterl, J. T., Haydon, P. G., et al. (2005). Gephyrin regulates the cell surface dynamics of synaptic GABAA receptors. *J. Neurosci.* 25, 10469–10478. doi: 10.1523/jneurosci.2267-05.2005

Jin, H., Chiou, T. T., Serwanski, D. R., Miralles, C. P., Pinal, N., and De Blas, A. L. (2014). Ring finger protein 34 (RNF34) interacts with and promotes GABAA receptor beta subunits. *Proc. Natl. Acad. Sci. U.S.A.* 111, E922–E931. doi: 10.1073/pnas.1525726113

Johnston, A. J., Kang, J. Q., Shen, W., Pickrell, W. O., Cushion, T. D., Davies, J. S., et al. (2014). A novel GABRB2 mutation, p.R136+104C, in a family with GEFS+ and extended phenotypes. *Neurobiol. Dis.* 64, 131–141. doi: 10.1016/j.nbd.2013.12.013
Joshí, S., Rajasekaran, K., Hawk, K. M., Brar, J., Ross, B. M., Tran, C. A., et al. (2015). Phosphatase inhibition prevents the activity-dependent trafficking of GABA(A) receptors during status epilepticus in the young animal. Epilepsia 56, 1355–1365. doi: 10.1111/epi.13098

Jurd, R., Tretter, V., Walker, J., Brandon, N. J., and Moss, S. J. (2010). Fyn kinase contributes to tyrosine phosphorylation of the GABA receptor gamma2 subunit. Mol. Cell. Neurosci. 44, 129–134. doi: 10.1016/j.mcn.2010.03.002

Kanamura, C., Haug, K., Sander, T., Runge, U., Gu, W., Hallmann, K., et al. (2002). A splice-site mutations in GABRG2 associated with childhood absence epilepsy and febrile convulsions. Arch. Neurol. 59, 1137–1141. doi: 10.1001/archneur.59.7.1137

Kanematsu, T., Jang, I. S., Yamaguchi, T., Nagahama, H., Yoshimura, K., Hidaka, K., et al. (2002). Role of the PLC-related, catalytically inactive protein p130 in GABA(A) receptor function. EMBO J. 21, 1004–1011. doi: 10.1093/emboj/21.5.1004

Kang, J. Q., and Macdonald, R. L. (2004). The GABA(A) receptor gamma2 subunit R43Q mutation linked to childhood absence epilepsy and febrile seizures causes retention of alpha1beta2gamma2S receptors in the endoplasmic reticulum. J. Neurosci. 24, 8672–8677. doi: 10.1523/jneurosci.2717-04.2004

Kang, J. Q., and Macdonald, R. L. (2016). Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. JAMA Neurol. 73, 1009–1016. doi: 10.1001/jamanetol.2016.0449

Kang, J. Q., Shen, W., and Macdonald, R. L. (2006). Why does fever trigger febrile seizures? GABA(A) receptor gamma2 subunit mutations associated with idiopathic generalized epilepsies have temperature-dependent trafficking deficiencies. J. Neurosci. 26, 2590–2597. doi: 10.1523/jneurosci.4243-05.2006

Kang, J. Q., Shen, W., and Macdonald, R. L. (2009). The GABRG2 mutation, Q351X, associated with generalized epilepsy with febrile seizures plus, has both loss of function and dominant-negative suppression. J. Neurosci. 29, 2845–2856. doi: 10.1523/jneurosci.4772-08.2009

Kang, J. Q., Shen, W., and Macdonald, R. L. (2013). Trafficking-deficient mutant GABRG2 subunit amount may modify epilepsy phenotype. Ann. Neurol. 74, 547–559. doi: 10.1002/ana.23947

Kano, M., Kano, M., Fukunaga, K., and Konnerth, A. (1996). Ca(2+)/calmodulin-dependent kinase contributes to tyrosine phosphorylation of the GABA receptor gamma2 subunit. Proc. Natl. Acad. Sci. U.S.A. 93, 13351–13356. doi: 10.1073/pnas.93.23.13351

Kawaguchi, S. Y., and Hirano, T. (2007). Sustained structural change of synapses from parvalbumin neurons causes wide-ranging behavioral alterations. Proc. Natl. Acad. Sci. U.S.A. 104, 4451–4456. doi: 10.1073/pnas.0605370104

Kittel, J. T., Chen, G., Hirano, T., et al. (2004). The gamma2 subunit of GABA(A) receptors is a GABARAPL1-binding site for clathrin AP2 adaptor protein-1 complex to GABA(A) receptors regulates the architecture of synaptic inhibition. J. Neurosci. 24, 11429–11438. doi: 10.1523/JNEUROSCI.3355-04.2004

Kokuk, T., Shinoda, K., Inoue, Y., and Kadoya, T. (2013). Dissociation of GABRG2 and GABAA receptors from parvalbumin neurons causes wide-ranging behavioral alterations. PLoS One 8:e59213. doi: 10.1371/journal.pone.0059213

Lee, K., Porteous, R., Campbell, R. E., Luscher, B., and Herbison, A. E. (2010). Knockdown of GABA(A) receptor signaling in GmRNA neurons has minimal effects upon fertility. Endocrinology 151, 4288–4346. doi: 10.1210/en.2010-0314

Lei, T. A., Chen, Z. W., Chang, C. S., and Olsen, R. W. (2004). GABAA receptor-associated protein traffics GABA(A) receptors to the plasma membrane in neurons. J. Neurosci. 24, 11429–11438. doi: 10.1523/jneurosci.3355-04.2004

Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 283–291. doi: 10.1038/nature19057

Leong, J. U., Stuckey, A. Lai, D., Skinner, J. R., and Love, D. R. (2015). Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations. BMC Med. Genet. 16:34. doi: 10.1186/s12881-015-0176-2

Leppa, E., Linden, A. M., Aller, M. I., Wulff, P., Vekosivcheva, O., Luscher, B., et al. (2016). Increased motor-impairing effects of the neuroactive steroid pregnanolone in mice with targeted inactivation of the GABA(A) receptor gamma2 subunit in the cerebellum. Front. Pharmacol. 7:403. doi: 10.3389/fphar.2016.00403

Lin, W. C., Davenport, C. M., Mourat, A., Vytla, D., Smith, C. M., Medeiros, K. A. et al. (2014). Engineering a light-regulated GABA(A) receptor for optical control of neural inhibition. ACS Chem. Biol. 9, 1414–1419. doi: 10.1021/cb500167u

Lin, W. C., Tsai, M.C., Davenport, C.M., Smith, C.M., Veit, J., Wilson, N.M., et al. (2015). A comprehensive optogenetic pharmacology toolkit for in vivo control of GABA(A) receptors and synaptic inhibition. Neuron 88, 879–891. doi: 10.1016/j.neuron.2015.10.026

Lionel, A. C., Vaags, A. K., Sato, D., Gazzelone, M. J., Mitchell, E. B., Chen, H. Y., et al. (2013). Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures. Hum. Mol. Genet. 22, 2055–2066. doi: 10.1093/hmg/ddt056

Lorenz-Guenther, J. M., and Jacob, T. C. (2017). GABA type A receptor trafficking and the architecture of synaptic inhibition. Dev. Neurobiol. 78, 238–270. doi: 10.1002/dneu.22536

Lorenz-Guenther, J. M., and Jacob, T. C. (2017). GABA type A receptor trafficking and the architecture of synaptic inhibition. Dev. Neurobiol. 78, 238–270. doi: 10.1002/dneu.22536

Macdonald, R. L., Bianch, M. T., and Feng, H. (2003). Mutations linked to generalized epilepsy in humans reduce GABA(A) receptor current. J. Neurosci. 23, 237–249. doi: 10.1523/jneurosci.0594-03.2003

Macdonald, R. L., Kang, I. Q., and Gallagher, M. J. (2012). GABA(A) Receptor Subunit Mutations and Genetic Epilepsies. Bethesda, MD: National Center for Biotechnology Information.
Rowland, A. M., Richmond, J. E., Olsen, J. G., Hall, D. H., and Bamber, B. A. (2006). Presynaptic terminals independently regulate synaptic clustering and autophagy of GABA receptors in Caenorhabditis elegans. J. Neurosci. 26, 1711–1720. doi: 10.1523/jneurosci.2727-05.2006

Saliba, R. S., Kretschmannova, K., and Moss, S. J. (2012). Activity-dependent phosphorylation of GABAA receptors regulates receptor insertion and tonic current. EMBO J. 31, 2937–2951. doi: 10.1038/emboj.2012.109

Sancar, F., and Czajkowski, C. (2004). A GABAA receptor mutation linked to human epilepsy (gamma2R43Q) impairs cell surface expression of alpha beta gamma receptors. J. Biol. Chem. 279, 47034–47039. doi: 10.1074/jbc.M403388200

Saunders, M. J., Szent-Gyorgyi, C., Fisher, G. W., Jarvik, J. W., Bruchez, M. P., and Waggoner, A. S. (2012). Fluorogen activating proteins in flow cytometry for the study of surface molecules and receptors. Methods 57, 308–317. doi: 10.1016/j.ymeth.2012.02.003

Schweizer, C., Balsiger, S., Bluthmann, H., Mansuy, I. M., Fritschi, J. M., Mohler, H., et al. (2003). The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses. Mol. Cell. Neurosci. 24, 442–450. doi: 10.1016/S1044-7431(03)00202-1

Shen, D., Hernandez, C. C., Shen, W., Hu, N., Poduri, A., Shiedley, B., et al. (2017). De novo GABRG2 mutations associated with epileptic encephalopathies. Brain 140, 49–67. doi: 10.1093/brain/aww272

Shen, Q., Fuchs, T., Sahir, N., and Luscher, B. (2012). Fluorogen activating proteins in flow cytometry for the study of surface molecules and receptors. Methods 57, 308–317. doi: 10.1016/j.ymeth.2012.02.003

Terunuma, M., Jang, I. S., Ha, S. H., Kittler, J. T., Kanematsu, T., Jovanovic, J. N., et al. (2004). GABAA receptor phospho-dependent modulation is regulated by phospholipase C-related inactive protein type 1, a novel protein phosphatase 1 anchoring protein. J. Neurosci. 24, 7074–7084. doi: 10.1523/JNEUROSCI.1323-04.2004

Tian, M., and Macdonald, R. L. (2012). The intronic GABRG2 mutation, IVS5+2T>G, associated with childhood absence epilepsy altered subunit mRNA intron splicing, activated nonsense-mediated decay, and produced a stable truncated gamma2 subunit. J. Neurosci. 32, 5937–5952. doi: 10.1523/JNEUROSCI.3332-11.2012

Tian, M., Mei, D., Freni, E., Hernandez, C. C., Granata, T., Shen, W., et al. (2013). Impaired surface alpha beta gamma GABA(A) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation. Neurobiol. Dis. 50, 135–141. doi: 10.1016/j.nbd.2012.10.008

Toma, C., Torricco, B., Hervas, A., Valdes-Mas, R., Tristan-Noguero, A., Padillo, V., et al. (2014). Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. Mol. Psychiatry 19, 784–790. doi: 10.1038/mp.2013.106

Tretter, V., Jacobo, T. C., Mukherjee, J., Fritschi, J. M., Pangalos, M. N., and Moss, S. J. (2008). The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J. Neurosci. 28, 1356–1365. doi: 10.1523/JNEUROSCI.0500-07.2008

Twelvetrees, A. E., Yuen, E. Y., Arancibia-Carcamo, I. L., MacAskill, A. F., Florian, C., et al. (2009). Deficits in spatial memory correlate with modified [gamma]-aminoxylic acid type A receptor tyrosine phosphorylation in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 106, 20039–20044. doi: 10.1073/pnas.0908441010

Uezu, A., Kanak, D. J., Bradshaw, T. W., Soderblom, E. J., Cataveiro, C. M., Burett, A. C., et al. (2016). Identification of an elaborate complex mediating postsynaptic inhibition. Science 353, 1123–1129. doi: 10.1126/science.aag08821

Vithlani, M., Hines, R. M., Zhong, P., Terunuma, M., Hines, D. J., Revilla-Hull, C. A., et al. (2012). Several behavioral traits and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus. J. Hum. Genet. 53, 769–774. doi: 10.1017/s102844640900105-y

Wafford, K. A., Burnett, D. M., Leidenheimer, N. J., Burt, D. R., Wang, J. B., Kofiji, P., et al. (1991). Ethanol sensitivity of the GABA(A) receptor expressed in Chinese hamster ovary cells. Mol. Pharmacol. 39, 298–310. doi: 10.1124/jn.39.1.298

Yan, Z., Smith, K. R., McAinsh, K., Chen, G., Arancibia-Carcamo, I. L., Haucke, V., et al. (2012). Delivery of GABAARs to synapses with super-resolution imaging. Proc. Natl. Acad. Sci. U.S.A. 109, 17536–17541. doi: 10.1073/pnas.1207044102

Zhang, J. S. (2003). The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J. Neurosci. 23, 7306–7317. doi: 10.1523/JNEUROSCI.0903-03.2003
in *Xenopus* oocytes requires 8 amino acids contained in the gamma 2L subunit. Neuron 7, 27–33. doi: 10.1016/0896-6273(91)90071-7

Wallace, R. H., Marini, C., Petrovs, S., Harkin, L. A., Bowser, D. N., Panchal, R. G., et al. (2001). Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat. Genet. 28, 49–52. doi: 10.1038/s8259

Wang, H., Bedford, F. K., Brandon, N. J., Moss, S. I., and Olsen, R. W. (1999). GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton. Nature 397, 69–72. doi: 10.1038/16264

Wang, J., Shen, D., Xia, G., Shen, W., Macdonald, R. L., Xu, D., et al. (2016). Differential protein structural disturbances and suppression of assembly partners produced by nonsense GABRG2 epilepsy mutations: implications for disease phenotypic heterogeneity. Sci. Rep. 6:35294. doi: 10.1038/srep35294

Wang, J. B., and Burt, D. R. (1991). Differential expression of two forms of GABAA receptor gamma 2-subunit in mice. Brain Res. Bull. 27, 731–735. doi: 10.1016/0361-9230(91)90054-N

Wang, R. A., Cheng, G., Kolaj, M., and Randic, M. (1995). Alpha-subunit of calcium/calmodulin-dependent protein kinase II enhances gamma-aminobutyric acid and inhibitory synaptic responses of rat neurons in vitro. J. Neurophysiol. 73, 2099–2106. doi: 10.1152/jn.1995.73.5.2099

Whiting, P., McKernan, R. M., and Iversen, L. L. (1990). Another mechanism for creating diversity in gamma-aminobutyrate type A receptors: RNA splicing directs expression of two forms of gamma 2 phosphorylation site. Proc. Natl. Acad. Sci. U.S.A. 87, 9966–9970. doi: 10.1073/pnas.87.24.9966

Wingrove, P. B., Thompson, S. A., Wafford, K. A., and Whiting, P. J. (1997). Key amino acids in the gamma subunit of the gamma-aminobutyric acidA receptor that determine ligand binding and modulation at the benzodiazepine site. Mol. Pharmacol. 52, 874–881. doi: 10.1124/mol.52.5.874

Wulff, P., Goetz, T., Leppa, E., Linden, A. M., Renzi, M., Swinny, J. D., et al. (2007). From synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors. Nat. Neurosci. 10, 923–929. doi: 10.1038/nn1927

Wulff, P., Ponomarenko, A. A., Bartos, M., Korotkova, T. M., Fuchs, E. C., Bahner, F., et al. (2009). Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc. Natl. Acad. Sci. U.S.A. 106, 3561–3566. doi: 10.1073/pnas.0813176106

Yamasaki, T., Hoyos-Ramirez, E., Martenson, J. S., Morimoto-Tomita, M., and Tomita, S. (2017). GARLH family proteins stabilize GABAA receptors at synapses. Neuron 93, 1138–1152.e6. doi: 10.1016/j.neuron.2017.02.023

Yuan, X., Yao, J., Norris, D., Tran, D. D., Bram, R. J., Chen, G., et al. (2008). Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABAA receptors. Mol. Cell. Neurosci. 38, 277–289. doi: 10.1016/j.mcn.2008.03.002

Zecharia, A. Y., Yu, X., Gotz, T., Ye, Z., Carr, D. R., Wulff, P., et al. (2012). GABAergic inhibition of histaminergic neurons regulates active waking but not the sleep-wake switch or propofol-induced loss of consciousness. J. Neurosci. 32, 13062–13075. doi: 10.1523/jneurosci.2931-12.2012

Zhang, M., Chakraborty, S. K., Sampath, P., Rojas, J. J., Hou, W., Saurabh, S., et al. (2015). Fluoromodule-based reporter/probes designed for in vivo fluorescence imaging. J. Clin. Invest. 125, 3915–3927. doi: 10.1172/JCI81086

Zhu, G., Yoshida, S., Migita, K., Yamada, J., Mori, F., Tomiyama, M., et al. (2012). Dysfuncion of extrasynaptic GABAergic transmission in phospholipase C-related, but catalytically inactive protein 1 knockout mice is associated with an epilepsy phenotype. J. Pharmacol. Exp. Ther. 340, 520–528. doi: 10.1124/jpet.111.182386

Zhu, S., Noviello, C. M., Teng, J., Walsh, R. M., Kim, J. I., and Hibbs, R. E. (2018). Structure of a human synaptic GABAA receptor. Nature 559, 67–72. doi: 10.1038/s41586-018-0255-3

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer MG and handling Editor declared their shared affiliation at the time of review.

Copyright © 2018 Lorenz-Guertin, Bambino and Jacob. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.